PegBio

About PegBio

PegBio Co., Ltd. is a clinical-stage biotechnology company established in 2008, focusing on the in-house development of therapies for chronic and metabolic diseases. The company operates within the biopharmaceutical sector, specifically targeting conditions with significant market potential such as type 2 diabetes mellitus (T2DM), obesity, and metabolic dysfunction-associated steatohepatitis (MASH). As a pre-revenue entity, PegBio's business model is centered on research and development, funded by significant venture capital backing and a recent initial public offering on the Hong Kong Stock Exchange. The company has conducted multiple financing rounds, attracting support from prominent industrial funds like YF Capital and Yingke PE.

The company's strategic focus is on leveraging its proprietary Highly Effective Target Screening & Molecule Modifier Platform (HECTOR®) to create a pipeline of drug candidates. This platform underpins their R&D efforts in drug molecular design. PegBio's pipeline currently consists of six product candidates, including a core product, PB-119. PB-119 is a long-acting GLP-1 receptor agonist administered via a once-weekly injection, designed for the treatment of T2DM and obesity. This product has demonstrated benefits in blood sugar control and weight management during clinical trials. The New Drug Application (NDA) for PB-119 for T2DM was accepted by China's National Medical Products Administration (NMPA) in September 2023, with a potential commercial launch in China anticipated in 2025.

PegBio is a publicly held company, having made its debut on the Hong Kong Stock Exchange in May 2025 to raise capital for the commercial launch of PB-119, further pipeline development, and general operations. The firm has yet to generate revenue from product sales and has reported significant R&D expenditures and net losses, which is characteristic of biotechnology companies in the development phase. To manage the substantial costs of bringing a drug to market, PegBio has indicated openness to collaborations, including licensing-out deals or joint commercialization efforts. The company faces a competitive landscape, with numerous other GLP-1 products already on or entering the market in China for both diabetes and obesity.